Dapagliflozin in the Treatment of Heart Failure with Diabetes Mellitus Type 2: a Systematic Review and Sequential Analysis
10.13748/j.cnki.issn1007-7693.20221358
- VernacularTitle:达格列净治疗心力衰竭合并2型糖尿病的系统评价及序贯分析
- Author:
Teng MA
1
;
Liting MU
2
;
Xintong TIAN
1
;
Ji YANG
1
;
Yingqiang ZHAO
2
Author Information
1. Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China
2. The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300250, China
- Publication Type:Journal Article
- Keywords:
dapagliflozin ； heart failure；type 2 diabetes mellitus；sequential analysis
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(7):968-978
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE :To systematically evaluate the clinical efficacy of dapagliflozin in the treatment of heart failure with diabetes mellitus type 2.
METHODS
The clinical trials of dapagliflozin in the treatment of heart failure with diabetes mellitus type 2 were searched in Embase, PubMed, Web of Science, Cochrane Library, VIP, CNKI and Wanfang databases from the establishment of the database to March 18, 2022. The RevMan 5.3 software was used for meta-analysis, and the TSA 0.9 software was used for sequential analysis.
RESULTS
The 31 RCT studies meeting the criteria were finally included, involving 2 906 patients. Meta-analysis showed that compared with the control group, the experimental group significantly improved LVEF[MD=4.43, 95% CI(3.35, 5.50), P<0.000 01], total effective rate[MD=4.19, 95%CI(2.52, 6.99), P<0.000 01], and reduced NT-proBNP[MD=–451.84, 95%CI(–608.09, –295.60), P<0.000 01], LVEDD[MD=–2.74, 95%CI(–3.67, –1.82), P<0.000 01, Hb1ac[MD=–0.88, 95%CI(–1.19, –0.57), P<0.000 01], FPG[MD=–1.10, 95%CI(–1.45, –0.75), P<0.000 01], 2hPG[MD=–2.52, 95%CI(–3.37, –1.66), P<0.000 01] and the incidence of adverse reactions[MD=0.63, 95%CI(0.47, 0.83), P=0.001]. Sequential analysis showed that the effect of dapagliflozin on LVEF in patients with heart failure with type 2 diabetes was accurate, and the possibility of excluding false positive was possible.
CONCLUSION
The treatment of heart failure with diabetes mellitus type 2 with good efficacy and safety is achieved by dapagliflozin, but it still needs to be included in more high-quality RCT studies for further demonstration.
